Notice Number: NOT-DA-09-024

RFP Available: N01DA-9-8889

Key Dates
Release Date: January 13, 2009
Proposal Due Date:  March 17, 2009

Issued by
National Institute on Drug Abuse (NIDA), ( http://www.nida.nih.gov )

The National Institute on Drug Abuse is soliciting proposals from qualified organizations capable of having in-house capability to develop methodologies and to perform in vivo rodent behavioral pharmacology for cocaine and other drug dependence disorders, using drug self-administration reinstatement models. The objectives of this contract are to determine the in vivo efficacy of novel compounds in animal models of relapse. This includes the following tests in animals trained to self-administer cocaine; (1) the ability of a test compound to block footshock- or other stressor-induced reinstatement of responding after a period of experimental extinction, (2) the ability of a test compound to block cocaine-priming-induced reinstatement of responding after a period of extinction, and (3) the ability of a test compound to block the effects of a conditioned cue (previously paired with cocaine) to reinstate responding for cocaine after a period of extinction.

This contract will be utilized by the NIDA, for the purpose of evaluating the efficacy of potential drug abuse treatment medications in rat models of relapse to cocaine self-administration. Test compounds will be evaluated for potency and efficacy in blocking reinstatement to one or more of these stimuli, in models of cocaine, methamphetamine, heroin, and possibly self-administration of other drugs of abuse. Test compounds will be shipped to the contractor for testing under blinded conditions with information regarding dose, vehicle and pretreatment time supplied by the NIDA project officer. The contractor will then evaluate the effects of the test compound for its effects to block reinstatement using a specific model and using standard protocols to be agreed upon in advance. Standardized, detailed reports with graphs will be prepared and submitted promptly to the program for each compound tested. Approximately 10-30 compounds per year will be evaluated using these protocols as specified by the NIDA project officer.

Due to the nature of the compounds that will be evaluated under this contract, it is mandatory that offerors possess a DEA Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970. In addition, the successful offeror must either possess, or demonstrate the ability to obtain a DEA registration for Schedule I controlled substances.

NIDA anticipates a 5-year cost reimbursement type contract with option quantities. One contract will be awarded.

RFP No. N01DA-09-8889 will be available electronically on or about January 29, 2009. You can access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov) or through the NIDA website: (URL: http://www.nida.nih.gov/RFP/RFPList.html). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Response to the RFP will be due on or about March 17, 2009. NIDA will consider proposals submitted by any responsible offeror. Following proposal submission and the initial review, the Contracting Officer may require additional documentation from offerors in the competitive range. This advertisement does not commit the Government to award a contract. Note 26. Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the contracting officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.

Inquiries

Point of Contact:

Brian O’Laughlin, Contract Specialist
National Institute on Drug Abuse, NIH
NIDA R&D Contracts Management Branch
6101 Executive Blvd., Room 260, MSC 8402
Bethesda, Maryland  20892-8402
Telephone: (301) 443-6677
Fax:  (301) 443-7595
E-mail: bo59d@nih.gov

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.